185 related articles for article (PubMed ID: 14562031)
1. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.
Ohana G; Bar-Yehuda S; Arich A; Madi L; Dreznick Z; Rath-Wolfson L; Silberman D; Slosman G; Fishman P
Br J Cancer; 2003 Oct; 89(8):1552-8. PubMed ID: 14562031
[TBL] [Abstract][Full Text] [Related]
2. CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.
Bar-Yehuda S; Madi L; Silberman D; Gery S; Shkapenuk M; Fishman P
Neoplasia; 2005 Jan; 7(1):85-90. PubMed ID: 15720820
[TBL] [Abstract][Full Text] [Related]
3. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.
Fishman P; Bar-Yehuda S; Ohana G; Barer F; Ochaion A; Erlanger A; Madi L
Oncogene; 2004 Apr; 23(14):2465-71. PubMed ID: 14691449
[TBL] [Abstract][Full Text] [Related]
4. Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents.
Bar-Yehuda S; Madi L; Barak D; Mittelman M; Ardon E; Ochaion A; Cohn S; Fishman P
Exp Hematol; 2002 Dec; 30(12):1390-8. PubMed ID: 12482500
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.
Bar-Yehuda S; Luger D; Ochaion A; Cohen S; Patokaa R; Zozulya G; Silver PB; de Morales JM; Caspi RR; Fishman P
Int J Mol Med; 2011 Nov; 28(5):727-31. PubMed ID: 21887476
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.
Ochaion A; Bar-Yehuda S; Cohn S; Del Valle L; Perez-Liz G; Madi L; Barer F; Farbstein M; Fishman-Furman S; Reitblat T; Reitblat A; Amital H; Levi Y; Molad Y; Mader R; Tishler M; Langevitz P; Zabutti A; Fishman P
Arthritis Res Ther; 2006; 8(6):R169. PubMed ID: 17101059
[TBL] [Abstract][Full Text] [Related]
7. Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists.
Bar-Yehuda S; Barer F; Volfsson L; Fishman P
Neoplasia; 2001; 3(2):125-31. PubMed ID: 11420748
[TBL] [Abstract][Full Text] [Related]
8. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection.
Fishman P; Bar-Yehuda S; Barer F; Madi L; Multani AS; Pathak S
Exp Cell Res; 2001 Oct; 269(2):230-6. PubMed ID: 11570815
[TBL] [Abstract][Full Text] [Related]
9. A3 adenosine receptor as a target for cancer therapy.
Fishman P; Bar-Yehuda S; Madi L; Cohn I
Anticancer Drugs; 2002 Jun; 13(5):437-43. PubMed ID: 12045454
[TBL] [Abstract][Full Text] [Related]
10. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.
Baharav E; Bar-Yehuda S; Madi L; Silberman D; Rath-Wolfson L; Halpren M; Ochaion A; Weinberger A; Fishman P
J Rheumatol; 2005 Mar; 32(3):469-76. PubMed ID: 15742438
[TBL] [Abstract][Full Text] [Related]
11. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.
Fishman P; Bar-Yehuda S; Ardon E; Rath-Wolfson L; Barrer F; Ochaion A; Madi L
Anticancer Res; 2003; 23(3A):2077-83. PubMed ID: 12894581
[TBL] [Abstract][Full Text] [Related]
12. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Silverman MH; Strand V; Markovits D; Nahir M; Reitblat T; Molad Y; Rosner I; Rozenbaum M; Mader R; Adawi M; Caspi D; Tishler M; Langevitz P; Rubinow A; Friedman J; Green L; Tanay A; Ochaion A; Cohen S; Kerns WD; Cohn I; Fishman-Furman S; Farbstein M; Yehuda SB; Fishman P
J Rheumatol; 2008 Jan; 35(1):41-8. PubMed ID: 18050382
[TBL] [Abstract][Full Text] [Related]
13. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor.
Ohana G; Bar-Yehuda S; Barer F; Fishman P
J Cell Physiol; 2001 Jan; 186(1):19-23. PubMed ID: 11147810
[TBL] [Abstract][Full Text] [Related]
15. Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation.
Morello S; Petrella A; Festa M; Popolo A; Monaco M; Vuttariello E; Chiappetta G; Parente L; Pinto A
Cancer Biol Ther; 2008 Feb; 7(2):278-84. PubMed ID: 18059189
[TBL] [Abstract][Full Text] [Related]
16. A3 adenosine receptor agonist potentiates natural killer cell activity.
Harish A; Hohana G; Fishman P; Arnon O; Bar-Yehuda S
Int J Oncol; 2003 Oct; 23(4):1245-9. PubMed ID: 12964011
[TBL] [Abstract][Full Text] [Related]
17. Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor-kappa B signaling.
Ren TH; Lv MM; An XM; Leung WK; Seto WK
J Dig Dis; 2020 Jan; 21(1):38-45. PubMed ID: 31714673
[TBL] [Abstract][Full Text] [Related]
18. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.
Bar-Yehuda S; Rath-Wolfson L; Del Valle L; Ochaion A; Cohen S; Patoka R; Zozulya G; Barer F; Atar E; Piña-Oviedo S; Perez-Liz G; Castel D; Fishman P
Arthritis Rheum; 2009 Oct; 60(10):3061-71. PubMed ID: 19790055
[TBL] [Abstract][Full Text] [Related]
19. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
Cohen S; Stemmer SM; Zozulya G; Ochaion A; Patoka R; Barer F; Bar-Yehuda S; Rath-Wolfson L; Jacobson KA; Fishman P
J Cell Physiol; 2011 Sep; 226(9):2438-47. PubMed ID: 21660967
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines.
Sakowicz-Burkiewicz M; Kitowska A; Grden M; Maciejewska I; Szutowicz A; Pawelczyk T
Arch Biochem Biophys; 2013 May; 533(1-2):47-54. PubMed ID: 23454010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
